B Cell

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.

WEST PALM BEACH, Fla. — Real-world effects of ublituximab after 1 year of administration were consistent with data from a pair of phase 3 clinical trials investigating the drug, according to a poster presented at ACTRIMS.

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal response, according to data published in The New England Journal of Medicine.

The FDA has cleared an investigational new drug application allowing a novel bispecific T-cell engager to begin a phase 1 trial in patients with active, moderate-to-severe systemic lupus erythematosus, according to a press release.

Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.

Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica spectrum disorder, Bruce A. Cree, MD, PhD, MAS, said in this Healio video.

CHICAGO — Negative circulating tumor DNA status contributed to a PFS benefit for patients with previously untreated diffuse large B-cell lymphoma, according to research presented at ASCO Annual Meeting.

A small percentage of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a second infusion of tisagenlecleucel had clinically meaningful responses, data from a retrospective study showed.

Brexucabtagene autoleucel continued to confer a greater than 70% complete remission rate among adults with relapsed or refractory B-cell acute lymphoblastic leukemia, results from the latest analysis of a pivotal phase 2 study showed.